5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome

A Randomized, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of 5-day Azacitidine for Patients With Lower-risk Myelodysplastic Syndrome

Approved dosing schedule of azacitidine for myelodysplastic syndrome (MDS) is 75 mg/m^2/day subcutaneous for 7 consecutive days every 28 days, which is based on the data from standard chemotherapy regimen and a Phase I safety clinical trial. Since the optimal dosage of this drug has not been found yet, it remains as a subject of clinical study that needs to be examined. If initial toxicity is minimized by developing dosage/regimen that replaces the standard therapy, it will be possible to provide continuous treatment with increased convenience by patients and treating physicians as well as improvement for safety in elderly patients or those with serious cytopenia. In addition, it is expected to lead to a better response by strictly keeping a treatment schedule.

Recent US study showed that 5-day regimen showed similar treatment results, but retrospective data from Spain showed lower response rate in 5-day regimen. Considering the recent circumstances around dosage and schedule of azacitidine in lower risk MDS, a Phase II clinical trial is planned in lower risk MDS patients in order to explore the efficacy in 5-day treatment by comparing prospectively with 7-day standard regimen.

Study Overview

• Status: Unknown
• Conditions: Myelodysplastic Syndrome
• Intervention / Treatment: Drug: Azacitidine

Detailed Description

• Using block randomization, subjects of Low or intermediate (INT)-1 patients will be equally allocated to the following two types of regimens.

  1. Group A: azacitidine 75mg/m^2 subcutaneously for 7 days every 28 days + best supportive care
  2. Group B: azacitidine 75mg/m^2 subcutaneously for 5 days every 28 days + best supportive care
• The study drug, azacitidine, is provided free of charge by Celgene until disease progression or relapse after response, or intolerable toxicity occurs in clinical study subject, or informed consent is withdrawn.
• No crossover between arms is allowed.
• Dose escalation in this study is not allowed; on the contrary, dose reduction or dose delay is possible based on adverse events and hematologic recovery.

• Study Type: Interventional
• Enrollment (Anticipated): 92
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Yoo-Jin Kim, MD, PhD; Phone Number: 82-2-2258-6057; Email: yoojink@catholic.ac.kr
• Study Contact Backup: Name: Kyungmin Kim; Phone Number: 82-2-2258-7926; Email: ddok9765@hotmail.com

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of, 137-701
    • Recruiting
    • Seoul st. mary's hospital
    • Contact: Yoo-Jin Kim, MD, PhD; Phone Number: 82-2-2258-6057; Email: yoojink@catholic.ac.kr
    • Contact: Kyungmin Kim; Phone Number: 82-2-2258-7926; Email: ddok9765@hotmail.com
  • Seoul, Korea, Republic of
    • Recruiting
    • Asan Medical Center
    • Contact: Je Hwan Lee, MD, PhD
  • Seoul, Korea, Republic of
    • Recruiting
    • Seoul National University Hospital
    • Contact: Sung Soo Yoon, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects must satisfy the following criteria in order to be enrolled in this clinical trial: Patients who have been diagnosed with MDS by the FAB criteria and belong to Low or INT-1 risk by the IPSS classification will be enrolled in this study. For the purpose of analysis, chronic myelomonocytic leukemia (CMML) patients with less than 5% of myeloblasts are also classified by the IPSS risk classification. Secondary or treatment-related MDS is allowed, but recurrent or persistent MDS after stem cell is not applicable. The enrolled patients should have anemia (hemoglobin < 10.0g/dL), transfusion dependence, thrombocytopenia (less than 100×10^9/L), or absolute neutrophil count less than 1.80×10^9/L.
• 18 years of age or older
• Life expectancy of at least 12 months
• ECOG performance status 2 or less
• Serum creatinine less than 1.5 times the upper limit of normal (ULN) level of the investigating institution
• Serum bilirubin less than 2.0 times the upper limit of normal (ULN) level of the investigating institution
• AST, ALT, and alkaline phosphatase less than 3 times the upper limit of normal (ULN) level of the investigation institution
• Patients who can have informed consent and signed the informed consent form
• Male patients who have a female partner of childbearing potential must agree to use two types of effective contraceptive methods during the study and for 30 days following the last dose.
• Females of childbearing potential (FCBP) must satisfy the following criteria: must agree to use the contraceptive method (oral contraceptives, injectables, hormonal implants; tubal ligation; intra uterine device; spermicidal contraceptives, the sterilized partner) approved by the physician during azacitidine treatment and for 3 months following the last dose, and must have a negative result of serum pregnancy test that was performed within 72 hours prior to starting study drug therapy.

Exclusion Criteria:

• Any coexisting major illness or organ failure
• HIV positive, or active hepatitis B or C infection
• Uncontrolled acute infection
• Uncontrolled hemorrhage
• Pregnant or lactating
• Known or suspected hypersensitivity to azacitidine
• Patients diagnosed with malignant hepatic carcinoma or malignant disease within the past 12 months (except in situ carcinoma without complication, cervical or breast intraepithelial neoplasia, or other local malignant carcinoma that is likely to be treated by surgical removal or radiotherapy)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 5-day arm; azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care	Drug: Azacitidine; 5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care; Other Names: vidaza
Active Comparator: 7-day arm; azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care	Drug: Azacitidine; 5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care; Other Names: vidaza

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate by modified IWG 2006 response criteria	Overall response rate is evaluated by assessing the percentage of patients with response (complete remission (CR), partial remission (PR), bone marrow CR, and hematologic improvement), response period, and transfusion requirement. Best response during at least 6 cycles of treatment will be assessed if there is no treatment failure or disease progression within 6 cycles of treatment. For patients who can keep the 4 week interval the Time Frame will be 25 weeks. The cycle interval can be extended up to 8 weeks which makes 49 weeks the maximum Time Frame.	After 6 cycles of treatment up to 25-49 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability	•Safety and tolerability profile of 5-day azacitidine in comparison with 7-day regimen. For patients who can keep the 4 week interval the Time Frame will be 25 weeks. The cycle interval can be extended up to 8 weeks which makes 49 weeks the maximum Time Frame.	After each course of treatment up to 25-49 weeks
Cytogenetic response rate by IWG 2006 response criteria	•Cytogenetic response of of 5-day azacitidine in comparison with 7-day regimen. For patients who can keep the 4 week interval the Time Frame will be 25 weeks. The cycle interval can be extended up to 8 weeks which makes 49 weeks the maximum Time Frame.	After 6 cycles of treatment up to 25-49 weeks

Collaborators and Investigators

• Sponsor: Seoul St. Mary's Hospital
• Collaborators: Celgene Corporation
• Investigators: Principal Investigator: Yoo-Jin Kim, MD, PhD, Division of hematology, Department of Internal Medicine, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital

Study record dates

Study Major Dates

• Study Start: March 1, 2012
• Primary Completion (Anticipated): June 1, 2016
• Study Completion (Anticipated): December 1, 2016

Study Registration Dates

• First Submitted: July 11, 2012
• First Submitted That Met QC Criteria: July 25, 2012
• First Posted (Estimate): July 30, 2012

Study Record Updates

• Last Update Posted (Estimate): November 20, 2015
• Last Update Submitted That Met QC Criteria: November 18, 2015
• Last Verified: November 1, 2015

More Information

Terms related to this study

• Keywords: myelodysplastic syndrome; azacitidine; dosing schedule
• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Disease; Bone Marrow Diseases; Hematologic Diseases; Precancerous Conditions; Syndrome; Myelodysplastic Syndromes; Preleukemia; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Azacitidine
• Other Study ID Numbers: VZ-MDS-PI-0267